bluebird bio(BLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLUE bluebird bio

Not Yet Opened 05-02 16:00:00 EDT

0.9033

-0.0060

-0.66%

盘后0.9176

+0.0143+1.58%

19:51 EDT

High0.9409	Low0.8800	Vol6.86M
Open0.9300	D1 Closing0.9093	Amplitude6.70%
Mkt Cap174.10M	Tradable Cap173.29M	Total Shares192.74M
T/O6.18M	T/O Rate3.58%	Tradable Shares191.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BLUE","market":"US","secType":"STK","nameCN":"bluebird bio","latestPrice":0.9033,"timestamp":1714680000000,"preClose":0.9093,"halted":0,"volume":6864439,"hourTrading":{"tag":"盘后","latestPrice":0.9176,"preClose":0.9033,"latestTime":"19:51 EDT","volume":127930,"amount":117114.2259,"timestamp":1714693905405},"delay":0,"floatShares":191839113,"shares":192741936,"eps":-0.898132,"marketStatus":"Not Yet Opened","change":-0.006,"latestTime":"05-02 16:00:00 EDT","open":0.93,"high":0.9409,"low":0.88,"amount":6181679.930855201,"amplitude":0.066975,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.898132,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1714723200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1371614400000,"exchange":"NASDAQ","adjPreClose":0.9093,"preHourTrading":{"tag":"盘前","latestPrice":0.93,"preClose":0.9093,"latestTime":"09:07 EDT","volume":6208,"amount":5769.3234752,"timestamp":1714655238014},"postHourTrading":{"tag":"盘后","latestPrice":0.9176,"preClose":0.9033,"latestTime":"19:51 EDT","volume":127930,"amount":117114.2259,"timestamp":1714693905405},"volumeRatio":0.930864},"requestUrl":"/m/hq/s/BLUE","defaultTab":"news","newsList":[{"id":"2432743416","title":"SHYFT GROUP SECURES FEDEX ORDER FOR BLUE ARC™ EV TRUCKS","url":"https://stock-news.laohu8.com/highlight/detail?id=2432743416","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2432743416?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:32","pubTimestamp":1714649520,"startTime":"0","endTime":"0","summary":"Blue Arc Expects to Deliver New Units Beginning Late 2024. NOVI, Mich., May 2, 2024 /PRNewswire/ -- The Shyft Group, Inc. , the North American leader in specialty vehicle manufacturing, assembly, and upfit for the commercial, retail, and specialty vehicle markets today announced a purchase order with FedEx for an initial order of 150 Blue Arc EV Trucks to be integrated into the FedEx pickup and delivery fleet in the U.S. This order reflects the shared commitment of both organizations to reduce carbon emissions and reduce air pollution through the adoption of commercial-grade electric vehicles .About The Shyft GroupThe Shyft Group is the North American leader in specialty vehicle manufacturing, assembly, and upfit for the commercial, retail, and service specialty vehicle markets. Our customers include first-to-last mile delivery companies across vocations, federal, state, and local government entities; the trades; and utility and infrastructure segments. The Shyft Group is organized int","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Esn.WHPTOjuqPtfERFlfcw--~B/aD0yMjg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f1faf3df74b19274b123b9d176ae582c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Esn.WHPTOjuqPtfERFlfcw--~B/aD0yMjg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f1faf3df74b19274b123b9d176ae582c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/shyft-group-secures-fedex-order-113200494.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/shyft-group-secures-fedex-order-113200494.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432430900","title":"LEADING PROXY ADVISORY FIRM ISS RECOMMENDS WHITESTONE REIT SHAREHOLDERS VOTE FOR CHANGE USING EREZ ASSET MANAGEMENT'S BLUE PROXY CARD","url":"https://stock-news.laohu8.com/highlight/detail?id=2432430900","media":"PR Newswire","top":-1,"share":"https://ttm.financial/m/news/2432430900?lang=en_us&edition=fundamental","pubTime":"2024-05-01 01:25","pubTimestamp":1714497900,"startTime":"0","endTime":"0","summary":"ISS Finds that Erez Makes a \"Compelling Case\" and Erez Nominee Bruce Schanzer Would Bring Relevant Shopping Center REIT Experience, an Independent Perspective, and a History of Engaging Collaboratively with Shareholders to the Board. Erez Encourages Whitestone Shareholders to Vote \"FOR\" Catherine Clark and Bruce Schanzer and to \"WITHHOLD\" from David Taylor and Nandita Berry Using the BLUE Proxy Card. NEW ROCHELLE, N.Y., April 30, 2024 /PRNewswire/ --Erez Asset Management, LLC , a shareholder of Whitestone REIT   which has nominated two candidates for election at Whitestone's upcoming 2024 Annual Meeting of Shareholders, today announced that Institutional Shareholder Services Inc. , a leading independent proxy advisory firm, has recommended shareholders vote on Erez's BLUE proxy card \"FOR\" Erez nominee Bruce Schanzer and \"WITHOLD\" from Whitestone nominee Nandita Berry.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qwcycQlBbl2luF_PH6LG4A--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/b4099a0a32e10be7c6434dab5b319d13","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qwcycQlBbl2luF_PH6LG4A--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/b4099a0a32e10be7c6434dab5b319d13"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leading-proxy-advisory-firm-iss-172500640.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leading-proxy-advisory-firm-iss-172500640.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430735101","title":"Bluebird Bio Faces Nasdaq Compliance Challenge and Delays","url":"https://stock-news.laohu8.com/highlight/detail?id=2430735101","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2430735101?lang=en_us&edition=fundamental","pubTime":"2024-04-27 04:23","pubTimestamp":1714163000,"startTime":"0","endTime":"0","summary":"The latest announcement is out from bluebird bio (BLUE). Bluebird bio, Inc. has been notified by Nasdaq that due to a delay in filing its annual fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bluebird-bio-faces-nasdaq-compliance-challenge-and-delays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bluebird-bio-faces-nasdaq-compliance-challenge-and-delays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2430353397","title":"BRIEF-Bluebird Bio Announces Receipt Of Expected Notice From Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2430353397","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2430353397?lang=en_us&edition=fundamental","pubTime":"2024-04-27 04:10","pubTimestamp":1714162206,"startTime":"0","endTime":"0","summary":"April 26 (Reuters) - bluebird bio Inc   :   * BLUEBIRD BIO ANNOUNCES RECEIPT OF EXPECTED NOTICE FROM NASDAQSource text for Eikon:    Further company coverage:    (Reuters.Briefs@thomsonreuters.com)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430735689","title":"bluebird bio receives non-compliance notice from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2430735689","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430735689?lang=en_us&edition=fundamental","pubTime":"2024-04-27 04:08","pubTimestamp":1714162097,"startTime":"0","endTime":"0","summary":"bluebird bio (NASDAQ:BLUE) on Friday said it has received a notice from Nasdaq, stating that because the company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023, it is no longer in compliance with listing rules.\nSource: Press Release","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095131-bluebird-bio-receives-non-compliance-notice-from-nasdaq","is_publish_highlight":false,"gpt_icon":0},{"id":"2430736826","title":"bluebird bio Announces Receipt of Expected Notice from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2430736826","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2430736826?lang=en_us&edition=fundamental","pubTime":"2024-04-27 04:05","pubTimestamp":1714161900,"startTime":"0","endTime":"0","summary":"SOMERVILLE, Mass., April 26, 2024----bluebird bio, Inc.  today announced that it received a notice  on April 24, 2024 from The Nasdaq Stock Market LLC  stating that because the Company has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 , it is no longer in compliance with Nasdaq Listing Rule 5250 , which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission .On April 16, 2024, bluebird previously announced that it would be delayed in filing its 2023 Form 10-K due to the need to restate the Company’s consolidated financial statements as of and for the year ended December 31, 2022 and unaudited financial information for each of the first three quarters of 2023 and 2022 in its 2023 Form 10-K. The notice from Nasdaq is standard practice in the event of a delayed 10-K filing and was anticipated.bluebird continues to forge new paths as a standalone commercial gene therapy company, combin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MPXqkOx2J5bSBMt92FmD4w--~B/aD0zNDg7dz0xMzkyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a68e958334a087292a68875fe34193af","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MPXqkOx2J5bSBMt92FmD4w--~B/aD0zNDg7dz0xMzkyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a68e958334a087292a68875fe34193af"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bluebird-bio-announces-receipt-expected-200500638.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430466319","title":"Crispr Therapeutics: Now Is The Time To Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2430466319","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430466319?lang=en_us&edition=fundamental","pubTime":"2024-04-25 00:40","pubTimestamp":1713976809,"startTime":"0","endTime":"0","summary":"For starters, we learned that the FDA along with other regulatory bodies around the world will approve this class of treatments, which was not a foregone conclusion back in the fall. CRISPR-Cas9 is a revolutionary gene editing tool which enables changing a DNA sequence, a process that is a huge breakthrough but also raises significant ethical concerns. These first approvals were a major milestone in the journey of this technological advancement. The commercial viability of these drugs is another matter entirely, and that should play out over the next couple of years, but with indications of how successful it will be in the next six to twelve months. The safest way to invest in a company like this would be to see real demand for these new treatments by patients, along with the associated revenues and cash flows. The problem is, by the time that happens, this stock will likely be much higher if it is indeed successful. I discuss the commercial viability in the risk section below, as thi","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/959053706/image_959053706.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/959053706/image_959053706.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4685695-crispr-therapeutics-now-is-the-time-to-buy","is_publish_highlight":false,"gpt_icon":0},{"id":"2430651904","title":"Hercules Capital: Winning Option In The Financial Services Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2430651904","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430651904?lang=en_us&edition=fundamental","pubTime":"2024-04-25 00:27","pubTimestamp":1713976053,"startTime":"0","endTime":"0","summary":"Bluestein presented the company’s strategies that have led to substantial profits and growth in assets under management: “…being able to operate an institutional venture and growth stage lending platform at scale, maintain robust liquidity and a strong balance sheet…thanks to the growth of both the BDC and our private credit funds business, Hercules Capital is now managing approximately $4.2 billion of assets, an increase of over 15% from where we were at year-end 2022.” The CEO elaborated on HTGC’s ability to “deliver achievements on multiple fronts in 2023, including record full year 2023 total gross fundings of $1.6 billion, an increase of 9.1% year-over-year… total investment income of $460.7 million, an increase of 43.2%… net investment income of $304 million, an increase of 61.7% year-over-year. Four consecutive years of delivering supplemental distributions to our shareholders.” Bluestein leveraged sports metaphors to sum up the essentially defensive strategy that has served HTG","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/636869698/image_636869698.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/636869698/image_636869698.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4685688-hercules-capital-winning-option-in-the-financial-services-space","is_publish_highlight":false,"gpt_icon":0},{"id":"2429994779","title":"BLUEBIRD BIO, INC. (NASDAQ: BLUE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2429994779","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2429994779?lang=en_us&edition=fundamental","pubTime":"2024-04-22 13:45","pubTimestamp":1713764700,"startTime":"0","endTime":"0","summary":"NEW YORK, April 22, 2024  -- Bernstein Liebhard LLP: Do you, or did you, own shares of bluebird bio, Inc. ?Did you purchase your shares between April 24, 2023 and December 8, 2023, inclusive?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23092683","is_publish_highlight":false,"gpt_icon":0},{"id":"2429696308","title":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2429696308","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2429696308?lang=en_us&edition=fundamental","pubTime":"2024-04-22 09:00","pubTimestamp":1713747600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of sto","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23092468","is_publish_highlight":false,"gpt_icon":0},{"id":"2428302935","title":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2428302935","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2428302935?lang=en_us&edition=fundamental","pubTime":"2024-04-18 09:00","pubTimestamp":1713402000,"startTime":"0","endTime":"0","summary":"NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of sto","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23081274","is_publish_highlight":false,"gpt_icon":0},{"id":"2428533547","title":"BLUE RIDGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Blue Ridge Bankshares, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2428533547","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2428533547?lang=en_us&edition=fundamental","pubTime":"2024-04-17 09:00","pubTimestamp":1713315600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Blue Ridge Bankshares, Inc. (NY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23075236","is_publish_highlight":false,"gpt_icon":0},{"id":"2428280385","title":"BUZZ-bluebird delays filing of Q1 and 2023 reports, shares fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2428280385","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2428280385?lang=en_us&edition=fundamental","pubTime":"2024-04-17 05:38","pubTimestamp":1713303494,"startTime":"0","endTime":"0","summary":"** Gene therapy developer bluebird bio's    shares fall ~3% to 96 cents in extended trading   ** Company says its Q1 2024 report and 2023 annual report filings will be delayed   ** Delays due to the need to restate financial statements for 2022 and for first three quarters of FY23, company says   ** Work required to complete all necessary procedures is taking longer than originally anticipated - BLUE   ** Up to last close, stock down 70.8% in the past 12 months ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428385157","title":"BRIEF-Bluebird Bio Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For The First Quarter Of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2428385157","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2428385157?lang=en_us&edition=fundamental","pubTime":"2024-04-17 05:36","pubTimestamp":1713303369,"startTime":"0","endTime":"0","summary":"April 16 (Reuters) - bluebird bio Inc   :   * BLUEBIRD BIO INC -  ANTICIPATES IT WILL BE DELAYED IN FILING ITS QUARTERLY REPORT ON FORM 10-Q FOR THE FIRST QUARTER OF 2024Source text for Eikon: [ID: Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428828800","title":"Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2428828800","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2428828800?lang=en_us&edition=fundamental","pubTime":"2024-04-17 04:26","pubTimestamp":1713299207,"startTime":"0","endTime":"0","summary":"- SEC Filing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/04/38280587/bluebird-bio-inc-anticipates-it-will-be-delayed-in-filing-its-quarterly-report-on-form-10-q-for-q1-","is_publish_highlight":false,"gpt_icon":0},{"id":"2427839983","title":"TD Cowen says sickle cell therapies may get higher CMS payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2427839983","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2427839983?lang=en_us&edition=fundamental","pubTime":"2024-04-16 04:46","pubTimestamp":1713214009,"startTime":"0","endTime":"0","summary":"TD Cowen said in a note that recently approved gene therapies by Vertex Pharmaceuticals /CRISPR  and bluebird bio  for sickle cell disease may get enhanced payments under proposed guidelines by the Centers for Medicare and Medicaid Services, or CMS. The investment bank said CMS’s draft annual update for the hospital inpatient Prospective Payment System proposes a new technology add-on payment, or NTAP, of 75% for the two new therapies rather than the usual 65% for NTAP products. Cowen added that the higher payment is modeled on an approach CMS employed to incentivize new anti-infectives.  Vertex/CRISPR’s Casgevy and bluebird’s Lyfgenia were approved by the FDA for sickle cell disease in December. Casgevy, a one-time gene therapy, reportedly costs around $2.2M.   More on bluebird bio, CRISPR Therapeutics, etc.  Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement What Vertex Pharm","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1156622320/image_1156622320.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1156622320/image_1156622320.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4089805-td-cowen-says-sickle-cell-therapies-may-get-higher-cms-payments","is_publish_highlight":false,"gpt_icon":0},{"id":"2427703783","title":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2427703783","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2427703783?lang=en_us&edition=fundamental","pubTime":"2024-04-14 09:00","pubTimestamp":1713056400,"startTime":"0","endTime":"0","summary":"NEW YORK, April 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of sto","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23063284","is_publish_highlight":false,"gpt_icon":0},{"id":"2426788833","title":"MCCAIN FOODS CANADA HITS A GRAND SLAM: LOCKS DOWN THREE-YEAR PARTNERSHIP WITH TORONTO BLUE JAYS","url":"https://stock-news.laohu8.com/highlight/detail?id=2426788833","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2426788833?lang=en_us&edition=fundamental","pubTime":"2024-04-12 19:00","pubTimestamp":1712919600,"startTime":"0","endTime":"0","summary":"Canada'siconic potato brand will serve as the Official French Fries of the Toronto Blue Jays, launches Fry Days with McCain at the ballpark to celebrate.TORONTO, April 12, 2024 /CNW/ - McCain Foods Canada , the world's largest manufacturer of prepared potato products, has signed a three-year partnership agreement with the Toronto Blue Jays.As part of the partnership, the Blue Jays and McCain are inviting Canadians to Make It A Fry Day with their family and friends during Fry Days with McCain at the ballpark. Exclusive to all Friday home games throughout the 2024 season, McCain will be premiering its specialty loaded fry recipe served in a reusable Blue Jays helmet. The specialty fry offer will be available as of the first Friday home game of the 2024 season at Rogers Centre, Friday April 12.For more information about upcoming programing and how to get exclusive access to Fry Days at the ballpark all season long, please follow @McCainCanada on social media for the latest updates and ann","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23059341","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bluebirdbio.com","stockEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":-0.2535},{"period":"3month","weight":-0.0552},{"period":"6month","weight":-0.7404},{"period":"1year","weight":-0.7781},{"period":"ytd","weight":-0.3454}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":-0.018091},{"month":2,"riseRate":0.545455,"avgChangeRate":0.015212},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.0983},{"month":4,"riseRate":0.363636,"avgChangeRate":-0.011785},{"month":5,"riseRate":0.636364,"avgChangeRate":0.025414},{"month":6,"riseRate":0.5,"avgChangeRate":0.108592},{"month":7,"riseRate":0.363636,"avgChangeRate":0.026911},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.003644},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.027559},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.055501},{"month":11,"riseRate":0.545455,"avgChangeRate":0.044741},{"month":12,"riseRate":0.454545,"avgChangeRate":0.012649}],"exchange":"NASDAQ","name":"bluebird bio","nameEN":"bluebird bio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"bluebird bio(BLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest bluebird bio(BLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"bluebird bio,BLUE,bluebird bio股票,bluebird bio股票老虎,bluebird bio股票老虎国际,bluebird bio行情,bluebird bio股票行情,bluebird bio股价,bluebird bio股市,bluebird bio股票价格,bluebird bio股票交易,bluebird bio股票购买,bluebird bio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"bluebird bio(BLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest bluebird bio(BLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction